GSK prepares to battle Pfizer in RSV vaccine market

London-GSKMore PLC found that an experimental vaccine against respiratory syncytial virus significantly reduced the risk of disease in a major trial, Pfizer What company in a corporation? expect a lucrative market.

Respiratory syncytial virus (RSV) is a common virus that proves fatal to approximately 14,000 older adults in the United States each year. Despite being identified decades ago, there is no licensed vaccine against the virus. It causes cold-like symptoms in most people, but can lead to more serious illnesses that affect the lungs of young babies and the elderly. I’m here. Analysts estimate it could be worth about $5 billion annually.